EXELA Pharma Sciences, LLC Receives Approval for Ganciclovir Injection in 0.8% sodium chloride solution, the First Ready to Use Ganciclovir Injection

Lenoir, NC February 17, 2017 – Exela Pharma Sciences today announced that it received FDA approval for Ganciclovir Injection in 0.8% sodium chloride solution. Ganciclovir Injection is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS) and for the prevention of CMV disease in adult transplant recipients at risk for CMV disease. Ganciclovir carries a boxed warning. Please see safety information below and additional important safety information in the full prescribing information by clicking here. Exela’s Ganciclovir Injection is the first ganciclovir product available in a ready to use formulation. 
Read More

Categories: company news and new product introduction.

EXELA Pharma Sciences, LLC Receives Approval for NIPRIDE RTU, (sodium nitroprusside) in 0.9% sodium chloride injection, the First Ready to Use sodium nitroprusside injection.

Lenoir, NC March 9, 2017 – Exela Pharma Sciences today announced that it received FDA approval for NIPRIDE RTU (sodium nitroprusside) in 0.9% sodium chloride injection, the company’s second FDA approval this year. NIPRIDE RTU (sodium nitroprusside) is indicated for the immediate reduction of blood pressure of adult and pediatric patients. NIPRIDE RTU is also indicated for producing controlled hypotension to reduce bleeding during surgery. NIPRIDE RTU is also indicated for the treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure,  peripheral vascular resistance and mean arterial blood pressure. NIPRIDE RTU carries a boxed
Read More

Categories: company news and new product introduction.

EXELA Pharma Sciences Receives Supplier Horizon Award from Premier Inc.

Lenoir, NC July 5, 2016 – Exela Pharma Sciences today announced that it is the winner of 2016 Supplier Horizon Award in Pharmaceutical Services and Technology by Premier, Inc. (NASDAQ: PINC). At a ceremony hosted by Premier in National Harbor, MD, Exela was recognized for its support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs. Mark Hartman, Exela’s Chief Commercial Officer, accepted the award. “It is a great honor to receive the Horizon Award from Premier, one of the leading healthcare improvement and transformation companies in our industry.
Read More

Categories: company news.

Exela Pharma Sciences Announces Availability of Verapamil HCl Injection, USP VIALS

Exela Pharma Sciences today confirmed the approval of its New drug Application (NDA) and availability of Verapamil HCl Injection, USP 5mg vials (2.5mg/ml). Product is stocked in the major wholesaler distribution channels, and is available in a convenient carton of 5 vials each. This lower pack size of 5 vials coupled with affordable contract pricing available through local Group Purchasing Organizations, leads to significant savings and lower inventory costs for hospitals and healthcare providers. The Verapamil HCl 5mg Injection vials also offer the convenience and safety of a vial versus an ampule. Exela’s Verapamil HCl Injection carries an AP rating
Read More

Categories: company news and new product introduction.